Diabetes Obes Metab. 2021 Aug 2. doi: 10.1111/dom.14513. Online ahead of print.
ABSTRACT
AIMS: To assess the efficacy and safety of sotagliflozin, a dual inhibitor of sodium-glucose cotransporter 1 and 2, in adults with type 2 diabetes (T2D) and stage 4 chronic kidney disease (CKD4).
MATERIALS AND METHODS: This 52-week, phase 3, randomized (1:1:1), placebo-controlled trial evaluated sotagliflozin 200 and 400 mg once daily in 277 patients with T2D and estimated glomerular filtration rate (eGFR) 15-30 mL/min/1.73 m2 . The primary endpoint was HbA1c reduction with sotagliflozin 400 mg vs. placebo at 26 weeks. A hierarchical statistical testing approach was used.
RESULTS: Baseline mean HbA1c was 8.3±1.0%; systolic blood pressure (SBP), 144±15 mmHg; and eGFR, 24±4 mL/min/1.73m2 . Placebo-adjusted changes with sotagliflozin 400 mg were -0.3% (95% CI -0.6 to 0.05; P=0.096) and -0.69% (-1.15 to -0.23; P=0.003) in HbA1c at weeks 26 and 52, respectively; -1.5 kg (-3.0 to -0.1) in body weight at week 26; -5.4 mmHg (-9.4 to -1.3) in SBP at week 12; and -0.3 mL/min/1.73m2 (-2.1 to 1.6; P=0.776) in eGFR at week 52. Over 52 weeks, 11.8%, 5.4%, and 3.3% patients receiving placebo and sotagliflozin 200 and 400 mg, respectively, required rescue therapy for hyperglycemia. Adverse events occurred in 82.8%, 86.2%, and 81.1% patients and serious cardiovascular adverse events occurred in 12.9%, 3.2%, and 4.4% patients in the placebo and sotagliflozin 200 and 400 mg groups, respectively.
CONCLUSIONS: After 26 weeks, HbA1c reductions with sotagliflozin were not statistically significant vs placebo in adults with T2D and CKD4. The 52-week safety profile was consistent with results of the SCORED outcomes trial (NCT03242018). This article is protected by copyright. All rights reserved.
PMID:34338408 | DOI:10.1111/dom.14513